Abstracts tagged "Cohort Study"

Abstract Number: 1539 • ACR Convergence 2021
High Disease Activity, as Assessed by RAPID3, Increases Risk of Hospitalization and Predicts Lower Chance of Recovery from COVID-19 in a Cohort of Tertiary Care Rheumatology Patients
Matas Orentas¹, Sonali Khandelwal², Michael Grant², Yanyu Zhang¹, Najia Shakoor² and Sobia Hassan¹, ¹RUMC, Chicago, IL, ²Rush University, Chicago, IL
Background/Purpose: There is a need to understand which patients with rheumatologic diseases may be at highest risk for poor COVID-19 related outcomes so that both…
Abstract Number: 0450 • ACR Convergence 2021
Identifying Trajectories of Radiographic Spinal Disease in Ankylosing Spondylitis
Mark Hwang¹, Minjae Lee², Lianne Gensler³, Matthew Brown⁴, Amirali Tahanan⁵, Mohammad Rahbar⁶, Theresa Hunter⁷, Mingyan Shan⁸, Mariko Ishimori⁹, John Reveille¹⁰, Michael Weisman¹¹ and Thomas Learch¹², ¹McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ²UT Southwestern, Dallas, TX, ³Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁴King's College London, London, United Kingdom, ⁵McGovern Medical School, Houston, TX, ⁶Division of Clinical and Translational Sciences, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, ⁷Eli Lilly and Company, Indianapolis, IN, USA, Indianapolis, IN, ⁸Eli Lilly and Company, Indianapolis, IN, ⁹Cedars-Sinai Health System, Los Angeles, CA, ¹⁰Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ¹¹Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹²Cedars-Sinai, Los Angeles, CA
Background/Purpose: Little is known about the natural history of spinal disease in Ankylosing Spondylitis (AS). Our objective was to identify distinct patterns of change in…
Abstract Number: 0833 • ACR Convergence 2021
Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in German Real-World Practice: Interim Results from a Post-Marketing Observational Study
Torsten Witte¹, Uta Kiltz², Florian Haas³, Elke Riechers⁴, Ulrich Prothmann⁵, Daniela Adolf⁶, Carsten Holland⁷, Rouven Hecht⁸, Alexander Rössler⁷, Kirsten Famulla⁸, Konrad Götz⁸ and Klaus Krüger⁹, ¹Hannover Medical School, Hannover, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ³Internistisch-Rheumatologische Facharztpraxis, Tübingen, Germany, ⁴Department for Rheumatology and Immunology, Hannover Medical University, Hannover, ⁵Knappschaftsklinikum Saar, Püttlingen, Germany, ⁶StatConsult GmbH, Biometry and Data Management, Magdeburg, Germany, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, ⁸AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁹Rheumatological Practice Center, Munich, Germany
Background/Purpose: Upadacitinib (UPA) is a Janus kinase inhibitor that has been shown to be effective and well tolerated in patients with rheumatoid arthritis (RA) in…
Abstract Number: 1540 • ACR Convergence 2021
Antibody Response After SARS-CoV-2 Infection in Patients with Rheumatic Diseases: A Multicenter, Nationwide Study
Ana Rita Cruz-Machado¹, Sofia Carvalho Barreira¹, Marc Veldhoen², Matilde Bandeira¹, Catarina Duarte³, Maria Rato⁴, Bruno Fernandes⁵, Salomé Garcia⁴, Filipe Pinheiro⁴, Miguel Bernardes⁴, Nathalie Madeira⁶, Cláudia Miguel⁶, Rita Torres⁷, Ana Bento Silva⁷, Carolina Mazeda⁸, Filipe Cunha Santos⁹, Marlene Sousa¹⁰, Hugo Parente¹¹, Maria José Santos¹², João Eurico Fonseca¹³ and Vasco C Romão¹³, ¹Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Center; Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ²Instituto de Medicina Molecular, João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ³Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ⁴Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Porto, Portugal, ⁵Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Braga, Portugal, ⁶Rheumatology Department, Instituto Português de Reumatologia, Lisbon, Portugal, ⁷Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal, ⁸Rheumatology Department - Centro Hospitalar do Baixo Vouga and Ibimed, Institute for Biomedicine, University of Aveiro, Aveiro, Portugal, ⁹Rheumatology Department, Local Health Unit of Guarda, Guarda, Portugal, ¹⁰Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ¹¹Rheumatology Department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal., Ponte de Lima, Portugal, ¹²Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, ¹³Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET); Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
Background/Purpose: The development and duration of humoral immunity after SARS-CoV-2 natural infection remains of interest. For the general population, available data suggest a robust immune…
Abstract Number: 0009 • ACR Convergence 2021
Humoral Immune Responses to SARS-CoV2 Infections and upon Vaccination Against SARS-CoV2
STEPHANIE FINZEL¹, Nicole Peter², Chiara Brand², Beate Fischer², Bärbel Keller², Sebastian Weigang³, Georg Kochs³, Martin Schwemmle³, Siegbert Rieg⁴, Philipp Mathé⁴, Winfried Kern⁴, Lia van der Hoek⁵, Kathrin de la Rosa⁶, Hans-Martin Jäck⁷, Klaus Warnatz², Reinhard Voll⁸ and Hermann Eibel², ¹University Clinic of Freiburg, Department of Rheumatology and Clinical Immunology, Freiburg, Germany, ²Department of Rheumatology and Clinical Immunology, Medical Faculty, University of Freiburg and Center for Chronic Immunodeficiency, Medical Center, University of Freiburg, Freiburg, Germany, ³Institute of Virology, University of Freiburg, Freiburg, Germany, ⁴Department of Infectiology, Medical Faculty, University of Freiburg, Freiburg, Germany, ⁵Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, Amsterdam, Netherlands, ⁶Max-Delbrück-Centrum für Molekulare Medizin (MDC), Berlin, Germany, ⁷Department of Medicine 3. Division of Immunology, Friedrich-Alexander-University Erlangen, Erlangen, Germany, ⁸Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany
Background/Purpose: We compared humoral immune responses against SARS-CoV-2 to responses against spike-antigen after vaccination.Methods: 800 health-care workers from University Medical Center Freiburg, Germany, were pursued…
Abstract Number: 0468 • ACR Convergence 2021
During Development of Rheumatoid Arthritis, Intermetatarsal Bursitis May Occur Before Clinical Joint Swelling: A Large MRI Study in Patients with Clinically Suspect Arthralgia
Bastiaan van Dijk¹, Fenne Wouters¹, Elise van Mulligen², Monique Reijnierse¹ and Annette H.M van der Helm-van Mil¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Inflammation of the synovial lining is a hallmark of rheumatoid arthritis (RA). A synovial lining is not only present at synovial joints and tendon…
Abstract Number: 0900 • ACR Convergence 2021
The Phenomenon of Fused Sacroiliac Joints but Absent Syndesmophytes in Long Standing Ankylosing Spondylitis Patients: Data from a Prospectively Followed Cohort
Lauren Ridley¹, Mark Hwang², John Reveille³, Lianne Gensler⁴, Mariko Ishimori⁵, Matthew Brown⁶, Mohammad Rahbar⁷, Amirali Tahanan⁸, Michael Ward⁹, Michael Weisman¹⁰ and Thomas Learch¹¹, ¹McGovern Medical School, Katy, TX, ²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ³Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁴Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁵Cedars-Sinai Health System, Los Angeles, CA, ⁶King's College London, London, United Kingdom, ⁷Division of Clinical and Translational Sciences, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, ⁸McGovern Medical School, Houston, TX, ⁹Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, United States, Rockville, MD, ¹⁰Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹¹Cedars-Sinai, Los Angeles, CA
Background/Purpose: Ankylosing Spondylitis describes disorders of inflammation and damage to the spine and sacroiliac (SI) joints. Clinicians have observed, on occasion, AS subjects with fused…
Abstract Number: 1640 • ACR Convergence 2021
Multisystem Inflammatory Syndrome in Children at Two Tertiary Hospitals in Cape Town, South Africa: Clinical Phenotype and Distinguishing Features from Similar Acute Inflammatory Conditions
Claire Butters¹, Deepthi Abraham², Heidi Facey-Thomas¹, Debbie Abrahams¹, Ayodele Faleye³, Helena Rabie², Christiaan Scott⁴, Liesl Zühlke⁵ and Kate Webb⁶, ¹Paediatric Rheumatology, University of Cape Town, Cape Town, South Africa, ²Tygerberg Hospital, Stellenbosch University, Cape Town, South Africa, ³Lagos state university teaching hospital Ikeja, Lagos, Nigeria, ⁴University of Cape Town, Faculty of Health Science, Cape Town, South Africa, ⁵Paediatric Cardiology, University of Cape Town, Cape Town, South Africa, ⁶University of Cape Town, Cape Town, South Africa
Background/Purpose: Distinguishing Multisystem Inflammatory Syndrome in Children (MIS-C) associated with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) from acute, pyrexial childhood illness can be challenging.…
Abstract Number: 0084 • ACR Convergence 2021
COVID-19 Pneumonia in Two Hospitals: Similar Outcomes Despite Differential Use of Tocilizumab
Leanna Wise¹, Lauren Mathias², Wendy Mack², Aarya Kafi³, Yash Kothari², Omkar Rao³ and William Stohl⁴, ¹LAC+USC/Keck Medicine of USC, Pasadena, CA, ²University of Southern California, Los Angeles, CA, ³University of California San Diego, San Diego, CA, ⁴University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: A substantial number of patients with COVID-19 pneumonia develop a hyperinflammatory state. The anti-IL-6 receptor (IL-6R) mAb tocilizumab (TCZ) has been used in such…
Abstract Number: 0478 • ACR Convergence 2021
Identification of Clinical Phenotypes of Hand Osteoarthritis Using Hierarchical Clustering Method
Marie Binvignat¹, Gabriel Pires¹, Nicolas Tchitchek¹, Alice Courties², Felicie Costantino³, David Klatzmann¹, Bernard Combe⁴, Maxime Dougados⁵, Pascal Richette⁶, Encarnita Mariotti-Ferrandiz¹, Francis Berenbaum⁷ and Jeremie Sellam⁸, ¹Sorbonne Universite, Paris, France, ²Service de Rhumatologie, AP-HP Hopital Saint-Antoine, Sorbonne Universite, INSERM, Centre de Recherche Saint-Antoine, Paris, France, ³Inserm, Boulogne Billancourt, France, ⁴CHU Montpellier Montpellier University, Montpellier, France, ⁵Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, ⁶Lariboisiere Hospital, Paris, France, ⁷Sorbonne Universit - hopital Saint-Antoine, Paris, France, ⁸INSERM UMRS_938, Sorbonne Université, St-Antoine Hospital, Paris, France, Paris, France
Background/Purpose: Hand osteoarthritis (OA) is an heterogenous disease in terms of risk factors, localization and severity. This heterogeneity also applies to the clinical presentation and…
Abstract Number: 0907 • ACR Convergence 2021
Radiographic Sacroiliitis Progression up to Six Years of Follow-Up in Patients with Non-Radiographic Axial Apondyloarthritis
Stan Kieskamp¹, Rick Wilbrink², Freke Wink³, Reinhard Bos⁴, Hendrika Bootsma¹, Suzanne Arends¹ and Anneke Spoorenberg¹, ¹University Medical Center Groningen, Groningen, Netherlands, ²University of Groningen, Leeuwarden, Netherlands, ³Medical Center Leeuwarden, Leeuwarden, Netherlands, ⁴Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden, Netherlands
Background/Purpose: In two years, approximately 10% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) progresses to ankylosing spondylitis (AS). There are no data available of more…
Abstract Number: 1652 • ACR Convergence 2021
Symptom Burden in Anti-citrullinated Protein Antibody Positive Individuals At-risk for Rheumatoid Arthritis Is Changing over Time and Comparable to Patients with Early Rheumatoid Arthritis
Paul Studenic¹, Alexandra Circiumaru², Daniel Aletaha³, Katerina Chatzidionysiou⁴, Anca Catrina⁵ and Aase Haj Hensvold⁶, ¹Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, ²Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden, ³Medical University Vienna, Vienna, Austria, ⁴Karolinska Institute, Division of Rheumatology; & Karolinska University Hospital, Rheumatology Unit, Stockholm, Sweden, ⁵Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁶Karolinska Institutet, Division for Rheumatology; & Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden
Background/Purpose: Symptom burden in individuals at risk for developing rheumatoid arthritis (RA) - positive for anti-citrullinated peptide antibodies (ACPA) and musculoskeletal complaints - has not…
Abstract Number: 0111 • ACR Convergence 2021
Risk of Hospitalization, Admission to Intensive Care and Mortality Due to COVID-19 in Patients with Rheumatic Diseases: A Population-based Matched Cohort Study
Ana Michelle Avina-Galindo¹, Shelby Marozoff¹, Zahra Fazal¹, Jessie Kwan¹, Na Lu¹, Alison Hoens², Diane Lacaille³, Jacek Kopec⁴, Hui Xie⁵ and J. Antonio Avina-Zubieta³, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada Arthritis Patient Advisory Board, Vancouver, BC, Canada, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴University of British Columbia, Richmond, BC, Canada, ⁵Simon Fraser University, Burnaby, BC, Canada
Background/Purpose: New cases of the novel coronavirus disease (COVID-19) continue to occur even one year since the declaration of a global pandemic. Although most people…
Abstract Number: 0480 • ACR Convergence 2021
Signs of Regression to the Mean in Observational Data from a Nation-Wide Exercise and Education Intervention for Osteoarthritis
Martin Englund¹, Dorte Grønne², Ewa Roos², Søren Skou² and Aleksandra Turkiewicz¹, ¹Lund University, Lund, Sweden, ²University of Southern Denmark, Odense, Denmark
Background/Purpose: Patients who enroll in interventions are likely to do so when they experience a flare-up in symptoms. This may create issues in interpretation of…
Abstract Number: 0959 • ACR Convergence 2021
Impact of Systemic Lupus Disease Activity State on Flare Risk After Hydroxychloroquine Maintenance, Reduction or Discontinuation in a Multinational Inception Cohort
Celline Brasil¹, John Hanly², Murray Urowitz³, Ann Clarke⁴, Rosalind Ramsey-Goldman⁵, Caroline Gordon⁶, Michelle Petri⁷, Ellen Ginzler⁸, Daniel Wallace⁹, Sang-Cheol Bae¹⁰, Juanita Romero-Diaz¹¹, Mary Anne Dooley¹², Christine Peschken¹³, David Isenberg¹⁴, Anisur Rahman¹⁵, Susan Manzi¹⁶, Soren Jacobsen¹⁷, S Sam Lim¹⁸, Ronald F van Vollenhoven¹⁹, Ola Nived²⁰, Andreas Jnsen²⁰, Diane Kamen²¹, Cynthia Aranow²², Guillermo Ruiz-Irastorza²³, Jorge Sanchez-Guerrero²⁴, Dafna Gladman²⁵, Paul R Fortin²⁶, Graciela Alarcn²⁷, Joan Merrill²⁸, Kenneth Kalunian²⁹, Manuel Ramos-Casals³⁰, Kristjan Steinsson³¹, Asad Zoma³², Anca Askanase³³, Munther Khamashta³⁴, Ian N. Bruce³⁵, Murat Inanc³⁶ and Sasha Bernatsky³⁷, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²Dalhousie University, Halifax, NS, Canada, ³Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵Northwestern University, Chicago, IL, ⁶Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, ⁸SUNY Downstate Health Sciences University, Brooklyn, NY, ⁹Cedars-Sinai, Los Angeles, CA, ¹⁰Hanyang University Medical Center, Seoul, Republic of Korea, ¹¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, ¹²Raleigh Neurology Associates, Chapel Hill, NC, ¹³University of Manitoba, Winnipeg, MB, Canada, ¹⁴Centre for Rheumatology, University College London, London, United Kingdom, ¹⁵University College London, London, United Kingdom, ¹⁶Allegheny Health Network, Wexford, PA, ¹⁷Rigshospitalet, Copenhagen, Denmark, ¹⁸Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ¹⁹Amsterdam University Medical Centers, Department of Rheumatology and Clinical Immunology, Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²⁰Lund University, Lund, Sweden, ²¹Medical University of South Carolina, Charleston, SC, ²²Feinstein Institutes for Medical Research, Manhasset, NY, ²³Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, ²⁴University Health Network, Toronto, ON, Canada, ²⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²⁶CHU de Quebec - Universite Laval, Québec City, QC, Canada, ²⁷University of Alabama at Birmingham, Birmingham, AL, ²⁸Oklahoma Medical Research Foundation, Oklahoma City, OK, ²⁹UC San Diego, La Jolla, CA, ³⁰Hospital Clinic, Barcelona, Barcelona, Spain, ³¹National University Hospital of Iceland, Reykjavik, Iceland, ³²University of Glasgow, East Kilbride, United Kingdom, ³³Columbia University Medical Center, New York, NY, ³⁴King's College London, London, United Kingdom, ³⁵University of Manchester, Manchester, United Kingdom, ³⁶Istanbul University Faculty of Medicine, Istanbul, Turkey, ³⁷McGill University, Montréal, QC, Canada
Background/Purpose: Physicians and patients often consider reducing or discontinuing hydroxychloroquine (HCQ) among SLE patients in remission or very low disease activity to limit HCQ-induced toxicity.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].